Should all patients with MM receive maintenance therapy after transplantation?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, about maintenance therapy after transplantation. We asked, Should all patients with MM receive maintenance therapy after transplantation?

Graham Jackson explains that we have a lot of evidence suggesting that maintenance therapy has an impact on progression-free survival (PFS) and overall survival (OS) in patients with MM. In particular, results from different studies show that lenalidomide (Revlimid®) maintenance, compared with placebo or no maintenance, significantly improves PFS and OS. In addition to lenalidomide, maintenance therapy with other agents, such as bortezomib (Velcade®) and ixazomib, significantly improves the outcomes of patients with MM. He concludes that, even though a lot of questions are still unanswered, maintenance therapy is important for all patients with MM after transplantation.